Information Provided By:
Fly News Breaks for November 8, 2016
HAE
Nov 8, 2016 | 09:30 EDT
Barrington analyst Michael Petusky upgraded Haemonetics to Outperform with a $41 price target citing the Q2 beat due to better-than-expected results in the plasma business coupled with a lower-than- expected decline in the blood center business. Following the results, the analyst believes Haemonetics' new leadership will be able to achieve its long-term goals.
News For HAE From the Last 2 Days
There are no results for your query HAE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.